Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rebekka Sterchi"'
Autor:
Anne W S Rutjes, Rebekka Sterchi, Katharina Liewald, Sven Trelle, Eveline Nüesch, Stephan Reichenbach, Douglas G. Altman, Peter Jüni
Publikováno v:
Arthritis & Rheumatism. 61:1633-1641
OBJECTIVE: To evaluate the association of adequate allocation concealment and patient blinding with estimates of treatment benefits in osteoarthritis trials. METHODS: We performed a meta-epidemiologic study of 16 meta-analyses with 175 trials that co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a457434c43843aedb5810f54a72639d
https://doi.org/10.1002/art.24894
https://doi.org/10.1002/art.24894
Publikováno v:
The Lancet. 364:2021-2029
Summary Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An increased risk of myocardial infarction had been observed in 2000 in the Vioxx Gastrointestinal Outcomes Research study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01890f39df1bba6cd1285bbac636f925
https://doi.org/10.1016/s0140-6736(04)17514-4
https://doi.org/10.1016/s0140-6736(04)17514-4
Autor:
Eveline Nüesch, Rebekka Sterchi, Stephan Reichenbach, Anne W S Rutjes, Peter Jüni, Sven Trelle
Publikováno v:
Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b81e6efa64a28f7f235edc470a868a42
https://doi.org/10.4414/smf.2010.07219
https://doi.org/10.4414/smf.2010.07219
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfcb73e54230303ae5347a474fc27826
https://doi.org/10.4414/fms.2010.07219
https://doi.org/10.4414/fms.2010.07219
Publikováno v:
Forum Médical Suisse ‒ Swiss Medical Forum. 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4cc7f09b09ce7470b610026659a5e6
https://doi.org/10.4414/fms.2010.07218
https://doi.org/10.4414/fms.2010.07218
Autor:
Anne W S Rutjes, Rebekka Sterchi, Manathip Osiri, Leonid Kalichman, Eveline Nüesch, Erik J.M. Hendriks, Peter Jüni, Stephan Reichenbach, Lucie Brosseau
Publikováno v:
The Cochrane Library
Rutjes, Anne Ws; Nüesch, Eveline; Sterchi, Rebekka; Kalichman, Leonid; Hendriks, Erik; Osiri, Manathip; Brosseau, Lucie; Reichenbach, Stephan; Jüni, Peter (2009). Transcutaneous electrostimulation for osteoarthritis of the knee. Cochrane database of systematic reviews, 2009(4), CD002823. Chichester: WileyInterscience 10.1002/14651858.CD002823.pub2
Scopus-Elsevier
Rutjes, Anne Ws; Nüesch, Eveline; Sterchi, Rebekka; Kalichman, Leonid; Hendriks, Erik; Osiri, Manathip; Brosseau, Lucie; Reichenbach, Stephan; Jüni, Peter (2009). Transcutaneous electrostimulation for osteoarthritis of the knee. Cochrane database of systematic reviews, 2009(4), CD002823. Chichester: WileyInterscience 10.1002/14651858.CD002823.pub2
Scopus-Elsevier
BACKGROUND: Osteoarthritis is the most common form of joint disease and the leading cause of pain and physical disability in the elderly. Transcutaneous electrical nerve stimulation (TENS), interferential current stimulation and pulsed electrostimula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82a502dd92dc99f349c243056a7750e9
https://pubmed.ncbi.nlm.nih.gov/21349043
https://pubmed.ncbi.nlm.nih.gov/21349043
Autor:
Ulrich Bürgi, Elizabeth Bürgi, Stephan Reichenbach, Peter Jüni, Martin Scherer, Rebekka Sterchi, Paul Dieppe, Sven Trelle
Publikováno v:
Annals of internal medicine. 146(8)
Previous meta-analyses described moderate to large benefits of chondroitin in patients with osteoarthritis. However, recent large-scale trials did not find evidence of an effect.To determine the effects of chondroitin on pain in patients with osteoar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaaf74dfd7296ff34f10e7a15ce7e518
https://pubmed.ncbi.nlm.nih.gov/18087065
https://pubmed.ncbi.nlm.nih.gov/18087065
Publikováno v:
ACC Current Journal Review. 14:15
Summary Background The cyclo-oxygenase 2 inhibitor rofecoxib was recently withdrawn because of cardiovascular adverse effects. An increased risk of myocardial infarction had been observed in 2000 in the Vioxx Gastrointestinal Outcomes Research study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::608a13daa9d91c77539c5bed39b5e319
https://doi.org/10.1016/j.accreview.2005.02.069
https://doi.org/10.1016/j.accreview.2005.02.069
Publikováno v:
BMJ. 326:334-334
Editor—Deeks et al say that celecoxib has improved gastrointestinal safety and tolerability compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs).1 We have several concerns. Firstly, Deeks et al reported the papers by Bensen et a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f20f79e6357a5777a738180271aa4a21
https://doi.org/10.1136/bmj.326.7384.334
https://doi.org/10.1136/bmj.326.7384.334